Action TKD TAKEDA PHARMACEUTICAL COMPANY LIMITED
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Takeda Pharmaceutical Company Limited Wiener Boerse

Actions

TKD

JP3463000004

Temps réel estimé Tradegate
Autres places de cotation
 15:54:22 17/06/2024 		Varia. 5j. Varia. 1 janv.
24,6 EUR +0,47% Graphique intraday de Takeda Pharmaceutical Company Limited -1,45% -5,15%
15:21 Mise à jour sectorielle : Les actions du secteur de la santé en baisse lundi avant le marché MT
14:13 Ovid prend ses distances avec son médicament contre l'épilepsie après que Takeda ait annoncé que les critères d'évaluation de la phase 3 n'ont pas été atteints -- Les actions de Pre-Bell chutent MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback
Sector Update: Health Care Stocks Decline Premarket Monday
Investors Look for Fresh Impetus Ahead of Holiday Break, Stifling US Equity Futures Pre-Bell
Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall
Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints
Takeda's Soticlestat Misses Goals in Phase 3 Epilepsy Studies
Takeda's seizure drug fails to meet main goal in late-stage studies
Takeda Pharmaceutical Company Limited Announces Topline Data from its Phase 3 SKYLINE and SKYWAY Studies Evaluating Soticlestat for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome
Takeda Pharmaceutical : Announces Phase 3 Topline Results for Soticlestat (TAK 935) in Patients with Dravet Syndrome and Lennox Gastaut Syndrome Form 6 K
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
Takeda Signs Option Agreement with Ascentage to License Leukemia Drug
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Takeda Pharmaceutical Company Limited Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, Third-Generation BCR-ABL Tyrosine Kinase Inhibitor
Takeda Issues New Shares, Disposes of Treasury Shares Under Long-term Incentive Plan for Employees
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
Takeda Pharmaceutical : Notice Concerning Issuance of New Shares and Disposal of Treasury Shares under the Long Term Incentive Plan for Company Group Employees Outside of Japan Form 6 K
Takeda Pharmaceutical Prices Second Hybrid Bonds for 460 Billion Yen
TAKEDA PHARMACEUTICAL : Form 6 K
Takeda Pharmaceutical : Statement from Masami Iijima, Chair of the Board of Directors Meeting of Takeda, in Response to Institutional Shareholder Services Inc.’s Voting Recommendations Ahead of the 148th Ordinary General Meeting of Shareholders Form 6 K
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 4502
  4. Action TKD
  5. Actualités Takeda Pharmaceutical Company Limited
  6. Autres langues